Dear all,
One of our endocrinologists was interested in cross reactivity of various insulin analogues with our assay (Abbott Architect). We measured spiked samples & found some variation in recovery, as would be expected due to sequence differences from human insulin. Eg Novorapid was ~80%, Lantus was ~130%.
However we were surprised that Actrapid, which should have an identical sequence to human insulin, read at ~80% of the expected value.
Does anyone have any ideas why this would be?
Thanks
Ben
Dr Ben Jones
SpR Metabolic Medicine / Chemical Pathology
Charing Cross Hospital
------ACB discussion List Information--------
This is an open discussion list for the academic and clinical community working in clinical biochemistry.
Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
Green Laboratories Work
http://www.laboratorymedicine.nhs.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/
|